Vital Therapies Inc (NASDAQ:VTL)’s share price rose 1.1% during trading on Monday . The company traded as high as $6.50 and last traded at $6.27. Approximately 8,273 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 286,035 shares. The stock had previously closed at $6.20.
VTL has been the topic of a number of recent analyst reports. BTIG Research reissued a “hold” rating on shares of Vital Therapies in a research note on Monday, May 28th. Zacks Investment Research raised Vital Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, May 12th. BidaskClub lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, April 10th. Finally, ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 28th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Vital Therapies has a consensus rating of “Hold”.
The company has a market capitalization of $275.40 million, a P/E ratio of -4.75 and a beta of 4.23.
Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.34) EPS for the quarter, hitting analysts’ consensus estimates of ($0.34). sell-side analysts expect that Vital Therapies Inc will post -1.23 EPS for the current year.
A number of institutional investors have recently bought and sold shares of the business. Citigroup Inc. lifted its stake in shares of Vital Therapies by 1,093.5% during the first quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock valued at $108,000 after acquiring an additional 14,576 shares during the period. Bank of Montreal Can acquired a new position in shares of Vital Therapies during the fourth quarter valued at $118,000. Dowling & Yahnke LLC acquired a new position in shares of Vital Therapies during the first quarter valued at $136,000. Two Sigma Investments LP acquired a new position in shares of Vital Therapies during the fourth quarter valued at $179,000. Finally, Annex Advisory Services LLC acquired a new position in shares of Vital Therapies during the first quarter valued at $190,000. 28.15% of the stock is currently owned by institutional investors.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.